Canmab 150mg Injection
MRP: ₹21,430.00
Packaging
1 INJECTION
Composition
Trastuzumab 150mg
Company
Biocon Ltd
MRP: ₹21,430.00
Packaging
1 INJECTION
Composition
Trastuzumab 150mg
Company
Biocon Ltd
| Medicine | Company | Price | You Save |
|---|---|---|---|
| Eleftha 150mg Injection | Intas | ₹6,225.00 | Save ₹15,205.00 |
| Ontramab 150mg Injection | Celon Labs | ₹10,500.00 | Save ₹10,930.00 |
| Hersima 150mg Injection | Alkem Labs | ₹19,132.00 | Save ₹2,298.00 |
| Hertraz 150mg Injection | Mylan Pharmaceuticals | ₹19,500.00 | Save ₹1,930.00 |
| Hermab 150mg Injection | RPG Life Sciences | ₹19,500.00 | Save ₹1,930.00 |
| Hervycta 150mg Injection | Dr. Reddy | ₹20,300.00 | Save ₹1,130.00 |
| Neuzumab 150mg Injection | Lupin | ₹20,500.00 | Save ₹930.00 |
| Trumab 150mg Injection | Glenmark | ₹20,600.00 | Save ₹830.00 |
| Vivitra 150mg Injection | Zydus Cadila | ₹22,400.00 | — |
| Trazumab 150mg Injection | Emcure Pharma | ₹23,210.00 | — |
| Trasturel 150mg Injection | Reliance | ₹24,200.00 | — |
Trastuzumab is an anti cancer medicine and is used in the treatment of following types of cancer
Chills, fever, headache, dizziness, back pain, arthralgia, increased cough, infection, insomnia, oedema, tachycardia, diarrhoea, paresthesia and rashes. Potentially Fatal: Severe hypersensitivity (anaphylaxis) and infusion reactions; pulmonary events e.g. acute respiratory distress syndrome; cardiotoxicity. Neutropenia (especially when given with chemotherapy).
Increased risk of severe cardiotoxicity with anthracyclines. Increased risk of leukopenia and anaemia in combination chemotherapy (e.g. paclitaxel). Paclitaxel may decrease the clearance of trastuzumab. Increased risk of bleeding with warfarin.
Lactation (start only 6 mth after last dose of drug). Do not admin by rapid IV or bolus inj.
Trastuzumab, a monoclonal antibody, has action directed against a cell surface protein produced by human epidermal growth factor receptor 2 (HER2). It inhibits proliferation of tumour cells that overexpress HER2 e.g. in 1/3 of breast cancer. Distribution: Vd: 44 mL/kg; unlikely to cross intact blood brain barrier. Excretion: Half-life ranges from 5.8 to 28.5 days after admin of the recommended doses.
Preexisting cardiac dysfunction and pulmonary disease (e.g. asthma, COPD), prior cardiotoxic therapy, extensive tumour involvement of lungs. Monitor cardiac function frequently and watch for signs of cardiotoxicity (ventricular dysfunction or CHF). Pregnancy, elderly.
Take orally with food and water, as directed by your physician.
Keep in a cool, dry place away from sunlight and moisture.
This content is for educational purposes only. Please consult your doctor before use.
| Brand Name | Form | Price |
|---|---|---|
| Abraxane 100mg Injection | INJECTION | ₹16,600.00 |
| Abstet 250mg Tablet 120s | TAB | ₹39,900.00 |
| Actiblok-100 IPR Tab | TAB | ₹95.00 |
| Actiblok-25 IPR Tab | TAB | ₹31.50 |
| Actiblok-50 IPR Tab | TAB | ₹47.77 |
| Actiblok-AM 25mg Tablet 10s | TAB | ₹60.00 |
| Actiblok-AM Tab 10s | TAB | ₹75.00 |
| Adnexa 10mg Inj. | INJECTION | ₹0.00 |
| Adnexa 50mg Inj. | INJECTION | ₹0.00 |
| Advacan 0.25mg Tab | TAB | ₹0.00 |
| Advacan 0.5mg Tab | TAB | ₹0.00 |
| Albubet Safe Infusion | INJECTION | ₹5,750.00 |
| Aretha 50mg Tablet 10s | TAB | ₹88.72 |
| Atsure 1.4gm Inj. | INJECTION | ₹0.00 |
| Atsure 1gm Inj. | INJECTION | ₹0.00 |
Written by: SastiMedic Medical Team
Reviewed by: Registered Pharmacist